Eli Lilly (LLY)

Eli Lilly and Company (NYSE:LLY) is pursuing a broad obesity portfolio designed to address different patient needs across treatment initiation, maintenance, efficacy, tolerability and dosing convenience, according to Ilya Yuffa, the company’s executive vice president and president of Lilly USA and G

The well-respected investor has Meta Platforms, Delta Air Lines, and Eli Lilly in his family office's portfolio. The stock isn't one of those.

Lilly may be impacted by Novartis' pelacarsen flop -- but not by much.

XLV's 0.08% expense ratio and 22.7% 1-year return outpace IXJ's global reach, but international diversification comes at a cost.

Demand for Novo Nordisk's new GLP-1 pill is rising quickly, while Eli Lilly's new pill faces an important headwind.

XPH delivered 57% returns over one year but swung 31% lower at its worst. IXJ offers steadier performance with higher income and $4.2 billion in assets for easier trading.

The worst may be in the rearview mirror for the drugmaker.

AMGN stock fell after Novartis' Pelacarsen trial failed, though Amgen's own Olpasiran and Repatha differ in mechanism and results, and analysts have kept price targets largely intact.

Eli Lilly is expanding into women's health, targeting endometriosis and pregnancy disorders by hiring experts and strategic investments.

During bear markets and recessions, it's good to be invested in "defensive" stocks and funds that hold up better than average.

Vanguard's broader healthcare portfolio charges less and yields more, but State Street's pharma-focused fund has delivered stronger recent gains despite higher volatility.

One fund offers broad sector exposure at 0.08% cost; the other concentrates on 30 biotech stocks with higher volatility but stronger recent returns.

FHLC captures the whole healthcare opportunity at rock-bottom cost. XPH narrows the bet to pharmaceuticals and charges significantly more for it.

This company aims to serve a market heading toward $100 billion.

CVS Health (NYSE:CVS) executives said the company is seeing improved momentum across its insurance, pharmacy, care delivery and balance-sheet priorities, while maintaining a cautious outlook on healthcare cost trends and several 2027 headwinds. Speaking at an investor conference, Chief Financial Of

Broad diversification and lower costs favor iShares, but Invesco's concentrated biotech bet delivered 47% returns in one year—at the cost of steeper drawdowns.

Hint: It's a good idea to buy the stock today.

Low-cost index funds can be a ticket to prosperity for everyday investors.

Eli Lilly (NYSE:LLY) has outperformed the market over the past 10 years by 16.85% on an annualized basis producing an average annual return of 30.5%. Currently, Eli Lilly has a market capitalization of $1.00 trillion.

Shares of Novo Nordisk are trading 66% below their 2024 high, but is that enough to call them cheap? Maybe.

JPMorgan sees healthcare ETF flows reversing, with Eli Lilly and AbbVie among stocks that could benefit from renewed sector rotation.

Eli Lilly (LLY) falls 2% amid a broader healthcare sell-off. Key support levels, technical breakdown, and market outlook analyzed.

Novartis and Ionis' high-profile Lp(a) flop on Friday reverberated through biotech stocks on Tuesday.

The big story today with Eli Lilly is its hugely successful GLP-1 drugs, but the long-term story is likely to be about its acquisitions.